Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review

Publication date: Available online 19 June 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell'Acqua, F. Kraja, A. Błażyńska-Spychalska, A.J. Łachiński, A. Surgo, R. Glynne-Jones, B.A. Jereczek-Fossa
BackgroundSBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases.Materials and methodsThe review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included.ResultsFor liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5-262.5 Gy (Grays). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3-262.5 Gy.ConclusionsSBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.



https://ift.tt/2tboJXG